Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.Amdinocillin Pivoxil: Pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin.Ceftizoxime: A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.Sulfamethizole: A sulfathiazole antibacterial agent.Magnesium Hydroxide: An inorganic compound that occurs in nature as the mineral brucite. It acts as an antacid with cathartic effects.Enterobacteriaceae: A family of gram-negative, facultatively anaerobic, rod-shaped bacteria that do not form endospores. Its organisms are distributed worldwide with some being saprophytes and others being plant and animal parasites. Many species are of considerable economic importance due to their pathogenic effects on agriculture and livestock.Biological Availability: The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Anti-Bacterial Agents: Substances that reduce the growth or reproduction of BACTERIA.Aluminum Hydroxide: A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.Microbial Sensitivity Tests: Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.Pamphlets: Printed publications usually having a format with no binding and no cover and having fewer than some set number of pages. They are often devoted to a single subject.Drug Labeling: Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.Patient Education as Topic: The teaching or training of patients concerning their own health needs.Formularies as Topic: Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Medical Records Systems, Computerized: Computer-based systems for input, storage, display, retrieval, and printing of information contained in a patient's medical record.alpha-Macroglobulins: Glycoproteins with a molecular weight of approximately 620,000 to 680,000. Precipitation by electrophoresis is in the alpha region. They include alpha 1-macroglobulins and alpha 2-macroglobulins. These proteins exhibit trypsin-, chymotrypsin-, thrombin-, and plasmin-binding activity and function as hormonal transporters.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Intellectual Property: Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)History, 18th Century: Time period from 1701 through 1800 of the common era.Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.History, 17th Century: Time period from 1601 through 1700 of the common era.Absorbable Implants: Implants constructed of materials designed to be absorbed by the body without producing an immune response. They are usually composed of plastics and are frequently used in orthopedics and orthodontics.Alloys: A mixture of metallic elements or compounds with other metallic or metalloid elements in varying proportions.Anti-Inflammatory Agents, Non-Steroidal: Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.Prostheses and Implants: Artificial substitutes for body parts, and materials inserted into tissue for functional, cosmetic, or therapeutic purposes. Prostheses can be functional, as in the case of artificial arms and legs, or cosmetic, as in the case of an artificial eye. Implants, all surgically inserted or grafted into the body, tend to be used therapeutically. IMPLANTS, EXPERIMENTAL is available for those used experimentally.Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.Sinusitis: Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.Mucociliary Clearance: A non-specific host defense mechanism that removes MUCUS and other material from the LUNGS by ciliary and secretory activity of the tracheobronchial submucosal glands. It is measured in vivo as mucus transfer, ciliary beat frequency, and clearance of radioactive tracers.Maxillary Sinusitis: Inflammation of the NASAL MUCOSA in the MAXILLARY SINUS. In many cases, it is caused by an infection of the bacteria HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS PNEUMONIAE; or STAPHYLOCOCCUS AUREUS.Viscosity: The resistance that a gaseous or liquid system offers to flow when it is subjected to shear stress. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)Food Coloring Agents: Natural or synthetic dyes used as coloring agents in processed foods.Nonprescription Drugs: Medicines that can be sold legally without a DRUG PRESCRIPTION.Student Health Services: Health services for college and university students usually provided by the educational institution.Preservatives, Pharmaceutical: Substances added to pharmaceutical preparations to protect them from chemical change or microbial action. They include ANTI-BACTERIAL AGENTS and antioxidants.Food Preservatives: Substances capable of inhibiting, retarding or arresting the process of fermentation, acidification or other deterioration of foods.Pharmacopoeias as Topic: Authoritative treatises on drugs and preparations, their description, formulation, analytic composition, physical constants, main chemical properties used in identification, standards for strength, purity, and dosage, chemical tests for determining identity and purity, etc. They are usually published under governmental jurisdiction (e.g., USP, the United States Pharmacopoeia; BP, British Pharmacopoeia; P. Helv., the Swiss Pharmacopoeia). They differ from FORMULARIES in that they are far more complete: formularies tend to be mere listings of formulas and prescriptions.Abbreviations as Topic: Shortened forms of written words or phrases used for brevity.Dictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Dictionaries, ChemicalTerminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.DictionaryNatural Language Processing: Computer processing of a language with rules that reflect and describe current usage rather than prescribed usage.Peptide Library: A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Immunoglobulin Heavy Chains: The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.Visual Prosthesis: Artificial device such as an externally-worn camera attached to a stimulator on the RETINA, OPTIC NERVE, or VISUAL CORTEX, intended to restore or amplify vision.
The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women. (1/20)
1. The pharmacokinetics of parenteral mecillinam (n = 27) and oral pivmecillinam (n = 12) were studied in pregnant (n = 27) and non-pregnant (n = 12) subjects. 2. In early pregnancy (9-14 weeks of gestation) the mean peak plasma drug concentration (Cmax = 19 +/- 9 micrograms ml-1) after an intravenous injection of 200 mg mecillinam was significantly lower (P less than 0.05) and the volume of distribution (V = 49 +/- 20.1) significantly larger (P less than 0.05) than in non-pregnant subjects (Cmax = 35 +/- 18 micrograms ml-1, V = 29 +/- 12.1). In late pregnancy (39-40 weeks of gestation) the plasma mean peak concentration (Cmax = (29 +/- 14 micrograms ml-1) after parenteral administration of 200 mg mecillinam was slightly lower and the volume of distribution (V = 65 +/- 29.1, V = 0.9 +/- 0.4 l kg-1) significantly larger than that in non-pregnant subjects (V = 0.4 +/- 0.3 l kg-1). Also after oral administration of 200 mg pivmecillinam, equimolar to 136.5 mg mecillinam, the mean peak plasma concentration in pregnant subjects (Cmax = 1.8 +/- 1.2 micrograms ml-1) was slightly lower than that in non-pregnant subjects (Cmax = 1.7 +/- 1.2 micrograms ml-1). 3. The mean half-life of elimination after parenteral administration of mecillinam was significantly longer during both early (t1/2,Z = 133 +/- 38 min, P less than 0.05) and late pregnancy (t1/2,Z = 107 +/- 41 min, P less than 0.05) as compared with the non-pregnant state (t1/2,Z = 75 +/- 21 min).(ABSTRACT TRUNCATED AT 250 WORDS) (+info)Ecological effects of perorally administered pivmecillinam on the normal vaginal microflora. (2/20)
The knowledge of the effects of antimicrobial agents on the normal vaginal microflora is limited. The objective of the present study was to study the ecological impact of pivmecillinam on the normal vaginal microflora. In 20 healthy women, the estimated day of ovulation was determined during three subsequent menstrual cycles. Microbiological and clinical examinations were performed on the estimated day of ovulation and on day 3 in all cycles and also on day 7 after ovulation in cycles 1 and 2. Anaerobic and facultative anaerobic gram-positive rods, mainly species of lactobacilli and actinomycetes, dominated the microflora. One woman was colonized on the third day of administration with a resistant Escherichia coli strain, and Candida albicans was detected in one woman on days 3 and 7 in cycle 2. No other major changes in the normal microflora occurred during the study. Administration of pivmecillinam had a minor ecological impact on the normal vaginal microflora. (+info)Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection. (3/20)
Similar changes in the periurethral and vaginal microflora were observed in 19 women with recurrent urinary tract infection following treatment with norfloxacin (NOR) or pivmecillinam (PIV). Escherichia coli strains were suppressed by both treatments. Staphylococcus spp. and enterococci colony counts increased following PIV treatment in the periurethral flora but remained stable with NOR. (+info)Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women. (4/20)
The primary infecting Escherichia coli strains from 156 women with community-acquired uncomplicated urinary tract infection (UTI) randomized to pivmecillinam or placebo and the E. coli strains causing UTI at two follow-up visits were typed using pulsed-field gel electrophoresis (PFGE). In the pivmecillinam treatment group PFGE showed that among patients having a negative urine culture at the first follow-up 77% (46/60) had a relapse with the primary infecting E. coli strain and 23% (14/60) had reinfection with a new E. coli strain at the second follow-up. Among patients having E. coli at the first follow-up PFGE showed that 80% (32/40) had persistence with the primary infecting E. coli strain, 15% (6/40) had reinfection with a new E. coli strain, and 5% (2/40) had different E. coli strains at the two follow-up visits (one had reinfection followed by relapse, and the other had persistence followed by reinfection). In the placebo group the majority had E. coli at the first follow-up. PFGE showed that among these patients 96% (50/52) had persistence with the primary infecting E. coli strain and 4% (2/50) had different E. coli strains at the two follow-up visits (both had persistence followed by reinfection). The finding that the majority of UTIs at follow-up are caused by the primary infecting E. coli strain supports the theory of a vaginal and rectal reservoir but could also support the recent discovery that E. coli strains are able to persist in the bladder epithelium despite appropriate antibiotic treatment, constituting a reservoir for recurrent UTI. (+info)Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. (5/20)
OBJECTIVE: To analyse associations between symptoms and bacteriuria in uncomplicated lower urinary tract infection in women (LUTIW) and to evaluate outcome of therapy with three different regimens of pivmecillinam or placebo. DESIGN: Prospective, multicentre, randomized, double-blind, and placebo-controlled therapy study. Symptoms registered at inclusion, during therapy and at follow-up visits after 8-10 and 35-49 days. Significant bacteriuria defined according to current European guidelines. SETTING: A total of 18 primary healthcare centres in northern Sweden. Subjects. Women aged 18 years and above with symptoms of urgency, dysuria, supra pubic or loin pain. Main outcome measures. Symptoms and bacteriuria at inclusion and course of symptoms, bacteriuria, and their combinations during and post-therapy. RESULTS: At inclusion, no associations or significant differences were found between symptom scores and bacteriuria, bacterial counts, or species. The 884 patients (77%) with significant bacteriuria were followed up. All pivmecillinam therapies were superior to placebo (p < 0.001). From day six until first follow-up, the mean values of all symptoms were higher and the bacteriological cure was lower at first follow-up in the three days (84%) compared with the seven days regimens (93-94%, p < 0.001). At final follow-up clinical cure was similar in all pivmecillinam regimens (65-72%) as was bacteriological cure (83-89%). Pivmecillinam had few low to mild adverse reactions, comparable to placebo. CONCLUSIONS: Symptoms are not conclusive for diagnosis of LUTIW. Pivmecillinam therapies are superior to placebo and seven days regimens are more efficient than three days. Pivmecillinam 200 mg x 2 x 7 days is recommended as a first-line therapy for LUTIW. (+info)Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil. (6/20)
Activity of simulated cefditoren urinary concentrations was determined against seven Escherichia coli isolates. Bactericidal activity was obtained from 4 to 24 h against TEM-1 (penicillinase production/hyperproduction), TEM-34 (IRT-6), and TEM-116 (extended-spectrum beta-lactamase [ESBL]) and from 6 to 8 h against SHV/TEM-116 (ESBL) but never against SHV/TEM-1 (ESBL). Extension of bactericidal activity depended on the resistance genotype/phenotype tested. (+info)Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial. (7/20)
(+info)Association between antimicrobial consumption and resistance in Escherichia coli. (8/20)
(+info)... (INN) or amdinocillin pivoxil (USAN, trade names Selexid, Penomax and Coactabs) is an orally active prodrug of ... Prodrugs that release pivalic acid when broken down by the body - such as pivmecillinam, pivampicillin and cefditoren pivoxil ... Pham P, Bartlett JG (August 28, 2008). "Amdinocillin (Mecillinam)". Point-of-Care Information Technology ABX Guide. Johns ...
... amdinocillin MeSH D03.438.260.825.124.036 --- amdinocillin pivoxil MeSH D03.438.260.825.249 --- cyclacillin MeSH D03.438. ... amdinocillin MeSH D03.605.084.737.124.036 --- amdinocillin pivoxil MeSH D03.605.084.737.249 --- cyclacillin MeSH D03.605. ...
... amdinocillin MeSH D02.065.589.099.750.124.036 --- amdinocillin pivoxil MeSH D02.065.589.099.750.249 --- cyclacillin MeSH ...
Amdinocillin * Amdinocillin Pivoxil * Amiloride * Amineptine * Aminophylline * Amitriptyline * Amitriptylinoxide * Amoxapine * ...
Amdinocillin. *Amdinocillin Pivoxil. *Amiloride. *Amineptine. *Aminophylline. *Amitriptyline. *Amitriptylinoxide. *Amoxapine. * ...
Amdinocillin * Amdinocillin Pivoxil * Amiloride * Amineptine * Aminophylline * Amitriptyline * Amitriptylinoxide * Amoxapine * ...
Amdinocillin. *Amdinocillin Pivoxil. *Amineptine. *Aminophylline. *Amiodarone. *Amitriptyline. *Amitriptylinoxide. *Amoxapine. ...
"Amdinocillin" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Amdinocillin" by people in Harvard Catalyst Profiles by year, ... Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency. Antimicrob Agents ... Below are the most recent publications written about "Amdinocillin" by people in Profiles. ...
Amdinocillin; Amdinocillin Pivoxil; Amicycline; Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin Sulfate; Aminosalicylic ... amdinocillin, amdinocillin pivoxil, amoxicillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, epicillin., ...
Alamecin; Alexidine; Amdinocillin; Amdinocillin Pivoxil; Amicycline; Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin ...
Pivmecillinam (INN) or amdinocillin pivoxil (USAN, trade names Selexid, Penomax and Coactabs) is an orally active prodrug of ... Prodrugs that release pivalic acid when broken down by the body - such as pivmecillinam, pivampicillin and cefditoren pivoxil ... Pham P, Bartlett JG (August 28, 2008). "Amdinocillin (Mecillinam)". Point-of-Care Information Technology ABX Guide. Johns ...
Amdinocillin Pivoxil Ceftriaxone Anti-Bacterial Agents Ciprofloxacin Antibiotic trials for community-acquired pneumonia. Fox, M ...
0027] The penicillins that may be used in the biodegradable implants include amdinocillin, amdinocillin pivoxil, amoxicillin, ...
... amdinocillin MeSH D03.438.260.825.124.036 --- amdinocillin pivoxil MeSH D03.438.260.825.249 --- cyclacillin MeSH D03.438. ... amdinocillin MeSH D03.605.084.737.124.036 --- amdinocillin pivoxil MeSH D03.605.084.737.249 --- cyclacillin MeSH D03.605. ...
The fluoroquinolones and pivmecillinam (amdinocillin pivoxil), although effective against Sd1 infection, are costly and usually ...
Amdinocillin pivoxil product Current Synonym true false 3716263012 Amdinocillin pivoxil-containing product Current Synonym true ... Product containing amdinocillin pivoxil Current Synonym true false 3499847013 Product containing mecillinam pivoxil Current ... Amdinocillin pivoxil Current Synonym true false 159106013 Amdinocillin pivoxil Current Synonym true false ... Amdinocillin pivoxil Current Synonym true false 3499846016 ...
Amdinocillin pivoxil Current Synonym true false 1492152015 Pivmecillinam Current Synonym true false ...
The penicillins that may be used in the biodegradable implants include amdinocillin, amdinocillin pivoxil, amoxicillin, ...
... amdinocillin, amdinocillin pivoxil, amebucort, amedalin, ametantrone, amezepine, amezinium metilsulfate, amfenac, amfepentorex ... valproate pivoxil, valproic acid, valpromide, valtrate, vancomycin hcl, vaneprim, vanillin, vanitolide, vanyldisulfamide, ... sulbactam pivoxil, sulbenicillin, sulbenox, sulbentine, sulbutiamine, sulclamide, sulconazole, sulfabenz, sulfabenzamide, ...
Amdinocillin, Amdinocillin Pivoxil, Amoxicillin, Ampicillin, Apalcillin, Aspoxicillin, Azidocillin, Azlocillin, Bacampicillin, ...
Amdinocillin *Amdinocillin Pivoxil *Amineptine *Aminophylline *Amiodarone *Amitriptyline *Amitriptylinoxide *Amoxapine * ...
4. ((antibiotic? or alamethicin? or amdinocillin? or amdinocillin pivoxil? or amikacin? or amoxicillin? or amoxicillin- ...
Amdinocillin pivoxil (in US); Selexid®. Available as. Tablets. Pivmecillinam is used to treat bacterial infections, such as ...
... amdinocillin explanation free. What is amdinocillin? Meaning of amdinocillin medical term. What does amdinocillin mean? ... Looking for online definition of amdinocillin in the Medical Dictionary? ... Amdinocillin , definition of amdinocillin by Medical dictionary https://medical-dictionary.thefreedictionary.com/amdinocillin ... amdinocillin. Also found in: Dictionary, Thesaurus, Encyclopedia. penicillin. [pen″ĭ-sil´in] any of a large group of natural or ...
Amdinocillin D2.886.675.966.500.750.124 D2.886.108.750.124. D4.75.80.875.99.221.750.124. Amdinocillin Pivoxil D2.886.675.966. ...
amdinocillin. *amdinocillin pivoxil. *amdinopenicillins. *AMDR. *AMDUCA. *AME. *ameba. *-ameba. *amebaism. *amebiasis. * ...
Find out information about amdinocillin. any of a group of chemically similar substances obtained from molds of the genus ... Penicillium that were the first antibiotic antibiotic, any of a variety of... Explanation of amdinocillin ... Amdinocillin , Article about amdinocillin by The Free Dictionary https://encyclopedia2.thefreedictionary.com/amdinocillin ... redirected from amdinocillin). Also found in: Dictionary, Thesaurus, Medical. penicillin,. any of a group of chemically similar ...
amdinocillin. *amdinocillin pivoxil. *amdinopenicillins. *AMDIS. *AMDISA. *AMDISS. *AMDIT. *AMDK. *AMDL. *AMDM. *AMDMC ...
- Prodrugs that release pivalic acid when broken down by the body - such as pivmecillinam, pivampicillin and cefditoren pivoxil - have long been known to deplete levels of carnitine. (wikipedia.org)